Cargando…

FGF23, Hypophosphatemia, and Emerging Treatments

FGF23 is an important hormonal regulator of phosphate homeostasis. Together with its co‐receptor Klotho, it modulates phosphate reabsorption and both 1α‐hydroxylation and 24‐hydroxylation in the renal proximal tubules. The most common FGF23‐mediated hypophosphatemia is X‐linked hypophosphatemia (XLH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imel, Erik A, Biggin, Andrew, Schindeler, Aaron, Munns, Craig F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Special Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715782/ https://www.ncbi.nlm.nih.gov/pubmed/31485552 http://dx.doi.org/10.1002/jbm4.10190

Ejemplares similares

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Craniosynostosis in Patients With X‐Linked Hypophosphatemia: A Review
por: Munns, Craig F, et al.
Publicado: (2023)

FGF23 and Vitamin D Metabolism
por: Latic, Nejla, et al.
Publicado: (2021)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Vitamin D Actions: The Lung Is a Major Target for Vitamin D, FGF23, and Klotho
por: Gayan‐Ramirez, Ghislaine, et al.
Publicado: (2021)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
por: Abramson, Matthew, et al.
Publicado: (2021)

Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations
por: Bosman, Ariadne, et al.
Publicado: (2023)

An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
por: Arora, Ipsa, et al.
Publicado: (2023)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage
por: Brandenburg, Vincent, et al.
Publicado: (2020)

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
por: Kato, Hajime, et al.
Publicado: (2023)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Downregulation of FGF Signaling by Spry4 Overexpression Leads to Shape Impairment, Enamel Irregularities, and Delayed Signaling Center Formation in the Mouse Molar
por: Marangoni, Pauline, et al.
Publicado: (2019)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia
por: Xiao, Zhousheng, et al.
Publicado: (2016)

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
por: Padidela, Raja, et al.
Publicado: (2021)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
por: Javaid, Muhammad Kassim, et al.
Publicado: (2021)

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
por: Suvannasankha, Attaya, et al.
Publicado: (2015)

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review
por: Lafage-Proust, Marie-Hélène
Publicado: (2022)

The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey
por: Skrinar, Alison, et al.
Publicado: (2019)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

The Emerging Role of Osteocytes in Cancer in Bone
por: Atkinson, Emily G, et al.
Publicado: (2019)

Emerging issues in peripheral nerve repair☆
por: Geuna, Stefano, et al.
Publicado: (2012)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25‐Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor‐23
por: Haussler, Mark R, et al.
Publicado: (2020)

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome
por: Glaspy, John A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kn3vkavun5jlmqaalu3mnph53n